Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL
Summary
Lymphoma is one of the fastest growing malignancies in the world, with an annual incidence rate of about 4%. Non-Hodgkin's lymphoma (NHL) is highly heterogeneous and can be broadly divided into two major categories, B-cell lymphoma and T/NK cell lymphoma. It is composed of diseases of different pathological types and malignant degrees, and the prognosis is not the same.The anti-PD-1 antibody may benefit patients with relapsed or refractory Hodgkin's lymphoma. At the same time, in non-Hodgkin's lymphoma, PD1 antibodies also show promising therapeutic prospects. We propose this research program, based on the previous research at home and abroad, to further clarify the role of PD-1 monoclonal antibody combined with chemotherapy in the treatment of relapsed and refractory NHL patients, evaluate its clinical efficacy and safety, and explore The best treatment strategy for patients with relapsed and refractory NHL in China.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Cytarabine | Small molecule | 2 g | — |
| Background | Cytarabine | Small molecule | 3 g | — |
| Background | Dexamethasone | Small molecule | 10 mg | — |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Epirubicin | Small molecule | 15 mg/m2 | — |
| Background | Etoposide | Small molecule | 50 mg/m2 | — |
| Background | Etoposide | Small molecule | 60 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Ifosfamide | Small molecule | 1 g/kg | — |
| Background | MTX | Unknown | 1 g | — |
| Background | MTX | Unknown | 3.5 g | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 0.4 mg/m2 | — |